IL13 and pulmonary fibrosis: Lebrikizumab is a humanized monoclonal antibody against interleukin-13 (IL-13) which has been used in trials studying the treatment of allergic asthma, atopic dermatitis, and idiopathic pulmonary fibrosis (IPF) by inhibiting the IL-13 driven Th2 inflammatory response [37–39].